Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceBusiness Wire • 04/10/24
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 MillionBusiness Wire • 03/19/24
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety DisorderBusiness Wire • 03/15/24
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program DesignBusiness Wire • 03/14/24
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive DisorderBusiness Wire • 03/13/24
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003Business Wire • 03/13/24
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT ProgramBusiness Wire • 02/07/24
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety DisorderBusiness Wire • 01/23/24
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 01/11/24
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028Business Wire • 01/08/24
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development ProgramsBusiness Wire • 01/04/24
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog ProgramBusiness Wire • 12/06/23
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline ResultsBusiness Wire • 12/05/23
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg DosesBusiness Wire • 11/30/23
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York CityBusiness Wire • 11/20/23
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023Business Wire • 11/16/23